ScreenerHero

CRON Cronos Group Inc.

TSX · CA · Healthcare · Drug Manufacturers - Specialty & Generic · thecronosgroup.com
4.670CAD+0.43%Mkt Cap: 1.25B $P/E: 17.96

Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporiz…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$65.69BUSDP/E 25.5
TAK
Takeda Pharmaceutical Company Limited
$57.82BUSD
TEVA
Teva Pharmaceutical Industries Limited
$45.64BUSDP/E 65.2
HLN
Haleon plc
$39.01BUSDP/E 18.1
ZTS
Zoetis Inc.
$29.48BUSDP/E 11.7
ZOE
Zoetis Inc.
$28.56BUSDP/E 12.2
UTHR
United Therapeutics Corporation
$23.23BUSDP/E 19.4
VTRS
Viatris Inc.
$20.15BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.27BUSDP/E 111.6
NBIX
Neurocrine Biosciences, Inc.
$14.79BUSDP/E 21.3
IPN
Ipsen S.A.
$12.60BUSDP/E 22.8
ELAN
Elanco Animal Health Incorporated
$11.23BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.40BUSDP/E 28.4
KRK
Krka, d. d.
$8.63BUSDP/E 19.3
AMRX
Amneal Pharmaceuticals, Inc.
$7.07BUSDP/E 41.4
ALKS
Alkermes plc
$6.99BUSDP/E 109.6
HIMS
Hims & Hers Health, Inc.
$6.88BUSD
LNTH
Lantheus Holdings, Inc.
$6.53BUSDP/E 24.2
KNSA
Kiniksa Pharmaceuticals International, plc
$5.93BUSDP/E 77.9
APTX
Apotex Health Corp.
$5.27BUSD

Key Statistics

Company
Market Cap1.25B USD
Enterprise Value692.89M USD
Revenue (TTM)130.42M USD
Gross Profit45.70M USD
Net Income (TTM)-6.88M USD
Revenue/Share0.47 CAD
Last Price4.670 CAD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees610
CountryCA
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINCA22717L1013
Valuation
P/E (Trailing)17.96
P/E (Forward)-76.83
PEG—
EV/EBITDA80.09
EV/Revenue5.31
P/S9.48
P/B1.12
EPS (TTM)0.26
EPS (Forward)-0.06
52W Range
3.23083% of range4.970
52W High4.970 CAD
52W Low3.230 CAD
Profitability
Gross Margin42.81%
Oper. Margin15.44%
EBITDA Margin6.63%
Profit Margin-6.44%
ROE-0.86%
ROA-0.79%
Growth
Revenue Growth58.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF18.84M USD
CapEx (TTM)18.98M USD
FCF Margin3.41%
FCF Yield0.35%
Net Debt-579.49M USD
Net Debt/EBITDA-66.99
Balance Sheet
Debt/Equity0.00
Current Ratio16.18
Quick Ratio15.15
Book Value/Sh4.11 CAD
Cash/Share2.16 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 CAD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:7
Split DateDec 17, 2014
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)5.237 CAD
Upside (mean)+12.2%
Target Range3.450 CAD – 7.000 CAD
3.450+12.2% to mean7.000
# Analysts4
Ownership
Shares Out.368.41M
Float186.99M
Insiders49.14%
Institutions15.51%
Short Interest
Short Ratio16.2d
Short % Float1.35%
Short % Out.0.67%
Shares Short2.46M
Short (prev mo.)2.87M
Technical
SMA 504.455 (+4.8%)
SMA 2003.885 (+20.2%)
Beta1.28
S&P 52W Chg14.58%
Avg Vol (30d)121.39K
Avg Vol (10d)102.45K
Technical Indicators
RSI (14)54.9
MACD0.0816
MACD Signal0.1009
MACD Hist.-0.0194
BB Upper4.913 CAD
BB Middle4.596 CAD
BB Lower4.280 CAD
BB Width13.77%
ATR (14)0.1422 CAD
Vol Ratio (20d)0.68x